BridgeBio have demonstrably advanced its development of a novel therapy for amyloid heart disease, employing the investigational drug. Initial clinical results reveals potential outcomes for patients suffering from the https://biotech444708.rimmablog.com/40812534/company-improves-attr-cm-therapy-with-the-drug